Abstract:Introduction: Chimeric antigen receptor-expressing T cells (CAR T cells) have revolutionized cancer treatment, particularly in B cell malignancies. However, the use of autologous T cells for CAR T therapy presents several limitations, including high costs, variable efficacy, and adverse effects linked to cell phenotype. Methods: To overcome these challenges, we developed a strategy to generate universal and safe anti-CD19 CAR T cells with a defined memory phenotype. Our approach utilizes CRISPR/Cas9 technology to target and eliminate the B2M and TRAC genes, reducing graft-versus-host and host-versus-graft responses. Additionally, we selected less differentiated T cells to improve the stability and persistence of the universal CAR T cells. The safety of this method was assessed using our CRISPRroots transcriptome analysis pipeline, which ensures successful gene knockout and the absence of unintended off-target effects on gene expression or transcriptome sequence. Results: In vitro experiments demonstrated the successful generation of functional universal CAR T cells. These cells exhibited potent lytic activity against tumor cells and a reduced cytokine secretion profile. The CRISPRroots analysis confirmed effective gene knockout and no unintended off-target effects, validating it as a pioneering tool for on/off-target and transcriptome analysis in genome editing experiments. Discussion: Our findings establish a robust pipeline for manufacturing safe, universal CAR T cells with a favorable memory phenotype. This approach has the potential to address the current limitations of autologous CAR T cell therapy, offering a more stable and persistent treatment option with reduced adverse effects. The use of CRISPRroots enhances the reliability and safety of gene editing in the development of CAR T cell therapies. Conclusion: We have developed a potent and reliable method for producing universal CAR T cells with a defined memory phenotype, demonstrating both efficacy and safety in vitro . This innovative approach could significantly improve the therapeutic landscape for patients with B cell malignancies.

A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies

CRISPR/Cas-based CAR-T cells: production and application

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy

CRISPR, CAR-T, and NK: Current applications and future perspectives

Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology

Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer

Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy

Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Recent advances in the production, reprogramming, and application of CAR-T cells for treating hematological malignancies

Engineering strategies to safely drive CAR T-cells into the future

CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy

CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More

Building Potent Chimeric Antigen Receptor T Cells with CRISPR Genome Editing

Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers

Current Clinical Application of the CAR-T Cell Therapy